Lung cancer
暂无分享,去创建一个
[1] Xue Wu,et al. Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing , 2020, Molecular oncology.
[2] Yanxi Han,et al. Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[3] Y. Shao,et al. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. , 2020, Pathology, research and practice.
[4] Y. Miyagi,et al. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next‐generation sequencing technique , 2020, Thoracic cancer.
[5] S. Murray,et al. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort , 2020, Journal for ImmunoTherapy of Cancer.
[6] A. Stenzinger,et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.
[7] M. Tiemann,et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC , 2020, Oncotarget.
[8] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[9] Shi-yue Li,et al. Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma , 2020, Orphanet Journal of Rare Diseases.
[10] P. Guo,et al. Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma , 2019, BMC Cancer.
[11] F. Grossi,et al. Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges , 2019, Cancers.
[12] Joe Y. Chang,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[13] Shuhang Wang,et al. TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer , 2019, Cancer Immunology Research.
[14] A. Drilon. TRK inhibitors in TRK fusion-positive cancers. , 2019 .
[15] K. Mertz,et al. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer , 2019, The Journal of pathology.
[16] M. Catalán,et al. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions , 2019, Molecular oncology.
[17] J. Lunceford,et al. OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC , 2019, Journal of Thoracic Oncology.
[18] J. Lunceford,et al. OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC , 2019, Journal of Thoracic Oncology.
[19] L. Bubendorf,et al. TCR-beta repertoire convergence and evenness are associated with response to immune checkpoint inhibitors , 2019, Annals of Oncology.
[20] R. Califano,et al. Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions , 2019, OncoTargets and therapy.
[21] J. Subramanian,et al. Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice , 2019, Cancers.
[22] David R. Jones,et al. Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach , 2019, Clinical Cancer Research.
[23] G. Burghel,et al. The importance of neoplastic cell content assessment and enrichment by macrodissection in cancer pharmacogenetic testing , 2019, Journal of Clinical Pathology.
[24] Minghui Wang,et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer , 2019, BMC Cancer.
[25] Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center , 2019, Molecular Biology Reports.
[26] Bin Xu,et al. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas , 2019, International Journal of Clinical Oncology.
[27] Larissa V Furtado,et al. Molecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis. , 2019, Archives of pathology & laboratory medicine.
[28] J. Kashima,et al. Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists , 2019, Cancers.
[29] V. Papadimitrakopoulou,et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.
[30] G. Otterson,et al. Liquid biopsy for lung cancers: an update on recent developments. , 2019, Annals of translational medicine.
[31] A. Addeo,et al. Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today? , 2019, Front. Oncol..
[32] Jing Zhao,et al. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel , 2019, JAMA oncology.
[33] S. Leroy,et al. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. , 2019, Journal of thoracic disease.
[34] F. López-Ríos,et al. Implementing TMB measurement in clinical practice: considerations on assay requirements , 2019, ESMO Open.
[35] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] T. Miyazaki,et al. Brief Report: Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[37] F. Barlesi,et al. The clinical utility of tumor mutational burden in non-small cell lung cancer. , 2018, Translational lung cancer research.
[38] P. Hofman,et al. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? , 2018, Translational lung cancer research.
[39] G. Lowman,et al. TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] Jacob Silterra,et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.
[41] N. Sunaga,et al. Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer , 2018, Cancers.
[42] Fiona Hyland,et al. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay. , 2018, Translational lung cancer research.
[43] Joe Y. Chang,et al. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.
[44] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[45] T. Qiu,et al. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. , 2018, Lung cancer.
[46] Yibo Gao,et al. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. , 2018, Cancer letters.
[47] P. Laurent-Puig,et al. TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma , 2018, Clinical Cancer Research.
[48] K. Reckamp. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[49] G. Rossi,et al. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. , 2018, Cancer treatment reviews.
[50] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[51] A. Shaw,et al. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer , 2018, Clinical Cancer Research.
[52] Shujiro Okuda,et al. Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung , 2018, Annals of Surgical Oncology.
[53] Robyn L. Temple-Smolkin,et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.
[54] Ahmet Zehir,et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[56] Radhe Mohan,et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] M. Berger,et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[59] M. Omata,et al. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. , 2017, European journal of cancer.
[60] A. Shaw,et al. Recent Advances in Targeting ROS1 in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[61] R. Bayliss,et al. EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients , 2017, Cancers.
[62] Joe Y. Chang,et al. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Final Results of a Phase 2 Study , 2017, JAMA oncology.
[63] A. Bezjak,et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.
[64] G. Troncone,et al. How to prepare cytological samples for molecular testing , 2017, Journal of Clinical Pathology.
[65] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[66] V. Miller,et al. BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies. , 2017 .
[67] R. Chiari,et al. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence , 2017, Medical Oncology.
[68] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[69] Markus Alber,et al. Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[70] D. Gerber,et al. ALK alterations and inhibition in lung cancer. , 2017, Seminars in cancer biology.
[71] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[72] G. Fontanini,et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D , 2016, The Journal of pathology.
[73] J. Minna,et al. Molecular Basis of Lung Carcinogenesis , 2017 .
[74] S. Ou,et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. , 2017, Lung cancer.
[75] AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.
[76] Di Yan,et al. Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy. , 2016, International journal of radiation oncology, biology, physics.
[77] Yufeng Shen,et al. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] A. Marchetti,et al. Review and Perspectives , 2022 .
[79] T. Solberg,et al. Technical Note: A treatment plan comparison between dynamic collimation and a fixed aperture during spot scanning proton therapy for brain treatment. , 2016, Medical physics.
[80] Shinichi Shimizu,et al. Optimization and evaluation of multiple gating beam delivery in a synchrotron-based proton beam scanning system using a real-time imaging technique. , 2016, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.
[81] Ji-Ying Song,et al. Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients , 2016, Cell reports.
[82] Ash A. Alizadeh,et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.
[83] J. Jen,et al. Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases , 2016, Modern Pathology.
[84] Zuofeng Li,et al. A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. , 2016, International journal of radiation oncology, biology, physics.
[85] Wei Liu,et al. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. , 2016, International journal of radiation oncology, biology, physics.
[86] J. Davison,et al. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging , 2016, Modern Pathology.
[87] Tatsuya Nakamura,et al. Dosemetric Parameters Predictive of Rib Fractures after Proton Beam Therapy for Early-Stage Lung Cancer. , 2016, The Tohoku journal of experimental medicine.
[88] P. Jänne,et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] C. Moran,et al. Primary Pulmonary Salivary Gland-type Tumors: A Review and Update , 2016, Advances in anatomic pathology.
[90] Xiaodong Zhang,et al. Reducing Dose Uncertainty for Spot-Scanning Proton Beam Therapy of Moving Tumors by Optimizing the Spot Delivery Sequence. , 2015, International journal of radiation oncology, biology, physics.
[91] S. Dearden,et al. Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review , 2015, Journal of experimental & clinical cancer research : CR.
[92] A. Nicholson,et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[93] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[94] G. Giaccone,et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[95] M. Mino‐Kenudson,et al. Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[96] Joe Y. Chang,et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[97] V. Seshan,et al. Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. , 2015, Cancer discovery.
[98] Sheryl K Elkin,et al. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types , 2015, Cell cycle.
[99] Y. Asmann,et al. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers , 2015, Scientific Reports.
[100] P. Hammerman,et al. Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics , 2015, Clinical Cancer Research.
[101] N. Girard,et al. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[102] Holly Ning,et al. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. , 2015, Clinical lung cancer.
[103] Aleksandra Markovets,et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.
[104] Baosheng Li,et al. Prospective study of special stage II (T2b-3N0M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy. , 2015, Journal of cancer research and therapeutics.
[105] Wei Liu,et al. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[106] T. Akimoto,et al. [Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction]. , 2015, Gan to kagaku ryoho. Cancer & chemotherapy.
[107] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[108] R. Doebele,et al. TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.
[109] W. D. Cress,et al. Lung cancer mutations and use of targeted agents in Hispanics. , 2015, Reviews on recent clinical trials.
[110] D. Gomez,et al. Poster PresentationThe 5-Year Outcome for Patients Diagnosed With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemotherapy and Proton Beam Therapy: Locally Advanced Non-Small Cell Lung Cancer , 2014 .
[111] Heng Li,et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. , 2014, International journal of radiation oncology, biology, physics.
[112] Yu Cao,et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.
[113] M. Tsao,et al. Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? , 2014, European Respiratory Journal.
[114] K. Nishio,et al. Targeting MET Amplification as a New Oncogenic Driver , 2014, Cancers.
[115] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[116] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[117] Ping Wang,et al. Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. , 2014, The British journal of radiology.
[118] H. Lee,et al. Effects of Fixation and Storage of Human Tissue Samples on Nucleic Acid Preservation , 2014, Korean journal of pathology.
[119] R. Shackelford,et al. ALK-rearrangements and testing methods in non-small cell lung cancer: a review , 2014, Genes & cancer.
[120] Joe Y. Chang,et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[121] L. Garraway,et al. Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.
[122] Y. Ichinose,et al. The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene. , 2013, Lung cancer.
[123] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[124] J. Slater,et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. , 2013, International journal of radiation oncology, biology, physics.
[125] G. Giaccone,et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.
[126] Geoffrey D. Hugo,et al. Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost. , 2013, International journal of radiation oncology, biology, physics.
[127] Zuofeng Li,et al. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer , 2013, Acta oncologica.
[128] L. Annemans,et al. Proton radiotherapy for locally-advanced non-small cell lung cancer, a cost-effective alternative to photon radiotherapy in Belgium? , 2013 .
[129] Radhe Mohan,et al. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. , 2012, International journal of radiation oncology, biology, physics.
[130] C. Ko,et al. Feasibility of Proton Therapy for Elective Nodal Irradiation in Patients With Locally Advanced Non-small Cell Lung Cancer , 2012 .
[131] Robert Gentleman,et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.
[132] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[133] U. Pastorino,et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. , 2012, Lung cancer.
[134] T. Nagayasu,et al. Clinical and molecular analysis of synchronous double lung cancers. , 2012, Lung cancer.
[135] I. Umelo,et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. , 2012, Lung cancer.
[136] Jeffrey W. Clark,et al. ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] Lei Dong,et al. A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. , 2012, International journal of radiation oncology, biology, physics.
[138] T. Hashimoto,et al. Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[139] Joe Y. Chang,et al. Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer , 2011, Cancer.
[140] K. Matsuo,et al. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] Joe Y. Chang,et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.
[142] J. Aster,et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. , 2011, Cancer research.
[143] H. Dienemann,et al. Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma , 2011, Journal of Clinical Pathology.
[144] M. Tsao,et al. EGFR mutations and lung cancer. , 2011, Annual review of pathology.
[145] Akira Mogi,et al. TP53 Mutations in Nonsmall Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.
[146] Joe Y. Chang,et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. , 2010, International journal of radiation oncology, biology, physics.
[147] J. Slater,et al. Comorbidity-Adjusted Survival in Early Stage Lung Cancer Patients Treated with Hypofractionated Proton Therapy , 2010, Journal of oncology.
[148] Christoph Bert,et al. Respiratory motion management in particle therapy. , 2010, Medical physics.
[149] William Pao,et al. Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases , 2009, The American journal of surgical pathology.
[150] A. Italiano,et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti‐EGFR treatment of a rare lung malignancy , 2009, International journal of cancer.
[151] T. Sakae,et al. Comparisons of Dose-Volume Histograms for Proton-Beam versus 3-D Conformal X-Ray Therapy in Patients with Stage I Non-Small Cell Lung Cancer , 2009, Strahlentherapie und Onkologie.
[152] K. Kubo,et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. , 2009, Japanese journal of clinical oncology.
[153] Y. Ishikawa,et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.
[154] Joe Y. Chang,et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[155] H. Baloglu,et al. The Effects of Tissue Fixation Alternatives on DNA Content: A Study on Normal Colon Tissue , 2008, Applied immunohistochemistry & molecular morphology : AIMM.
[156] Yuki Togashi,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.
[157] Simon Chapman,et al. Impact of tobacco control policies and mass media campaigns on monthly adult smoking prevalence. , 2008, American journal of public health.
[158] J. Aster,et al. BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.
[159] Yih-Leong Chang,et al. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. , 2007, The Journal of thoracic and cardiovascular surgery.
[160] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[161] Joe Y. Chang,et al. Stereotactic body radiation therapy for stage I non-small cell lung cancer. , 2007, Thoracic surgery clinics.
[162] Joe Y. Chang,et al. 4D Proton treatment planning strategy for mobile lung tumors. , 2007, International journal of radiation oncology, biology, physics.
[163] W. Travis,et al. Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors. , 2007, Japanese journal of clinical oncology.
[164] Radhe Mohan,et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.
[165] Takehiko Fujisawa,et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis , 2006, Modern Pathology.
[166] F. Cappuzzo,et al. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.
[167] R Tibshirani,et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification , 2006, Oncogene.
[168] S. Hirohashi,et al. Array‐based comparative genomic hybridization analysis of high‐grade neuroendocrine tumors of the lung , 2005, Cancer science.
[169] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[170] S. Senan,et al. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer. , 2004, Lung cancer.
[171] Carl Virtanen,et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles , 2004, The Lancet.
[172] J. Testa,et al. Chromosomal imbalances in human lung cancer , 2002, Oncogene.
[173] Y. Miyagi,et al. Aberrant Nuclear Localization and Gene Mutation of β-catenin in Low-Grade Adenocarcinoma of Fetal Lung Type: Up-Regulation of the Wnt Signaling Pathway May Be a Common Denominator for the Development of Tumors that Form Morules , 2002, Modern Pathology.
[174] Angela Greco,et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium , 2000, Oncogene.
[175] J C Rosenwald,et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.
[176] A. Scharl,et al. Expression of p16 and lack of pRB in primary small cell lung cancer , 1999, The Journal of pathology.
[177] J M Slater,et al. Proton-beam radiotherapy for early-stage lung cancer. , 1999, Chest.
[178] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[179] David I. Smith,et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers , 1998, Oncogene.
[180] J. Minna,et al. Cigarettes, sex, and lung adenocarcinoma. , 1997, Journal of the National Cancer Institute.